FilingsTodayST Pharm
At a glance
ST Pharm filed 64 disclosures in the last 12 months, including 6 insider, 6 5% holder, 4 earnings and 3 contract. The most recent key filing was on Oct 27: Operating profit ₩15.7B, up 6.6% YoY. Revenue ₩97.6B, up 19.1% YoY.
Revenue for 2025 was ₩332B, up 21.2% on 2024. Operating margin was 16.6% against 10.1% a year earlier. Debt was 32% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩175B and operating profit of ₩29.8B.
The 2025 annual report lists 1,560 employees with an average tenure of 6.8 years and average pay of ₩68M, #657 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩165M each on average. It paid ₩500 per common share in cash dividends, against ₩500 a year earlier (+0%). 동아쏘시오홀딩스(주) and related parties held 37.65% at year end.
From the 2025 annual report
Staff: 1,560 (1,118 men, 442 women), of whom 96 on fixed-term contracts. Total pay for the year: ₩106B. Directors and auditors: 6, paid ₩840M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩500 | ₩500 | ₩500 |
| Payout ratio | 18.3% | 30.8% | 48% |
| Yield (as filed) | 0.33% | 0.58% | 0.81% |
| Total cash dividends | ₩10.1B | ₩10.1B | ₩9.4B |
Largest shareholder
동아쏘시오홀딩스(주) holds 29.45%; with 4 related parties the group holds 37.65% of common shares at year end (from 38.67% at the start of the year).
Auditor: 삼정회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
New contracts, last 12 months
1 new supply contract worth 28% of the revenue stated in the filings.
Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.